|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||3.8800 - 3.8800|
|52-week range||3.8800 - 3.8800|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
WALTHAM, Mass., March 25, 2023--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturda